Cumberland Pharmaceuticals (CPIX) revenue breakdown
By product, Sancuso is the largest at 27% of fiscal 2025 revenue; Product - Other grew fastest, 46% a year over 3 years.
Revenue by product
Fiscal years, as Cumberland Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $45M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sancuso | — | — | — | — | — | — | — | — | $9M | $12M | 27% |
| Kristalose | — | — | — | — | — | — | — | — | $15M | $11M | 24% |
| Vibativ | — | — | — | — | — | — | — | — | $7M | $9M | 21% |
| Caldolor | — | — | — | — | — | — | — | — | $5M | $5M | 10% |
| Product - Other | — | — | — | — | — | — | $1M | $2M | $1M | $4M | 9% |
| Product - Talicia | — | — | — | — | — | — | — | — | — | $3M | 7% |
| Acetadote | — | — | — | — | — | — | — | — | $185,182 | $508,169 | 1% |
| RediTrex | — | — | — | — | — | — | — | — | $90,237 | $11,391 | 0% |
| Product | — | — | — | — | — | — | $41M | $38M | — | — | — |
| Product | — | — | — | — | — | $35M | — | — | — | — | — |
| Product | $32M | — | — | — | — | — | — | — | — | — | — |
| Kristalose | — | $11M | $12M | $13M | $16M | — | — | — | — | — | — |
| Caldolor | — | — | $5M | $9M | $11M | — | — | — | — | — | — |
| Ethyol | — | $11M | — | — | — | — | — | — | — | — | — |
| Vibativ | — | $4M | $5M | $5M | $5M | — | — | — | — | — | — |
| Totect | — | $4M | — | — | — | — | — | — | — | — | — |
| Acetadote | — | $7M | $4M | $4M | $2M | — | — | — | — | — | — |
| Vaprisol | — | $2M | $2M | $936,615 | $1M | — | — | — | — | — | — |
| Other | — | — | — | — | — | $939,784 | — | — | — | — | — |
| RediTrex | — | — | — | — | $856,657 | — | — | — | — | — | — |
| Other | $547,375 | — | — | — | — | — | — | — | — | — | — |
| Omeclamox-Pak | — | $2M | $623,297 | $837,829 | $257,088 | — | — | — | — | — | — |
| Omeclamox | — | — | — | — | — | — | — | — | -$3,075 | -$10,436 | -0% |
| Vaprisol | — | — | — | — | — | — | — | — | -$174,538 | -$18,346 | -0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CPIX.
Open CPIX in InvestinglyQuestions
Where does Cumberland Pharmaceuticals make its money?
In fiscal 2025, by product: Sancuso $12M, Kristalose $11M, Vibativ $9M, Caldolor $5M, Product - Other $4M.
From Cumberland Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.